PharmAla Biotech Holdings, Inc. ( (TSE:MDMA) ) has provided an update.
PharmAla Biotech Holdings Inc. has successfully completed the shipment of its LaNeo™ MDMA to UCLA for a clinical trial investigating schizophrenia. This marks the first shipment of MDMA capsules across the American/Canadian border, highlighting the company’s role in addressing the unmet need for MDMA in the United States for clinical trial use. The trial, led by Dr. Bershad and Dr. Marder, faced challenges due to regulatory approvals, but PharmAla is committed to supporting the research, which could significantly contribute to the scientific understanding of MDMA.
More about PharmAla Biotech Holdings, Inc.
PharmAla Biotech Holdings Inc. is a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules, including MDMA. The company aims to alleviate the global backlog of generic, clinical-grade MDMA for clinical trials and commercial sales in selected jurisdictions, while also developing novel drugs in the same class. PharmAla is the only company currently providing clinical-grade MDMA for patient treatments outside of clinical trials and emphasizes strong regulatory relationships.
YTD Price Performance: -33.33%
Average Trading Volume: 261,766
Technical Sentiment Consensus Rating: Hold
Learn more about MDMA stock on TipRanks’ Stock Analysis page.